Skip to content

US · MDXG · BIOTECHNOLOGY

MiMedx Group, Inc. (MDXG) intrinsic value and stock valuation

$3.05as of 2026-11-21 · Mkt cap 606.36M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MiMedx Group, Inc. DCF and intrinsic value

InvestorsCraft values MDXG with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MDXG’s statements →

MiMedx Group, Inc. Graham Number

Graham Number: $3.58d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Marietta, GA 30062 mimedx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$418.6M+11% 5y CAGRd
20112025
Net income
$48.6M
20112025
Free cash flow
$73M
20112025
Total equity
$256.6M+22.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$418.6M$348.9M$321.5M$267.8M$242M
Operating income$63.9M$58.9M$37.1M-$-14.73M-$-7.05M
Net income$48.6M$42.4M$67.4M-$-30.2M-$-12.3M
EPSd$324.5K$284.6K$462K-$-267.47K-$-111.46K
Operating cash flow$74M$66.2M$26.8M-$-17.89M-$-1.98M
Capital expenditure-$-1.03M-$-1.68M-$-1.99M-$-1.51M-$-3.22M
Free cash flow$73M$64.5M$24.8M-$-19.41M-$-5.2M
Total assets$342.7M$263.9M$239.1M$171.4M$187.9M
Total debt$22.5M$24.8M$48.1M$52.5M$53.3M
Net debt-$-143.59M-$-79.57M-$-33.9M-$-13.48M-$-33.79M
Total equity$256.6M$193.1M$142.7M$74.5M$92.6M
Cash and short-term investments$166.1M$104.4M$82M$66M$87.1M
Income statement
20252024202320222021
Revenue$418.6M$348.9M$321.5M$267.8M$242M
Cost of revenue$73M$60.1M$54.6M$48.3M$39.6M
Gross profit$345.6M$288.8M$266.8M$219.5M$202.4M
Research and development expenses$15.1M$12.3M$12.7M$12.7M$9.93M
Selling, general and administrative expenses$266.2M$216.4M$216.3M$220.9M$194.9M
Other expenses$0.00$1.21M$760K$700K$4.66M
Operating expenses$281.3M$229.9M$229.7M$234.3M$209.4M
Cost and expenses$354.7M$290M$284.4M$282.6M$249.1M
Interest income$4.72M$0.00$0.00$0.00$0.00
Interest expense$1.78M$1.01M$6.46M$5.02M$4.98M
Depreciation and amortization$14.9M$6.04M$3.43M$4.05M$5.18M
Ebitda$82.9M$65.4M$40.5M-$-10.69M-$-1.89M
Operating income$63.9M$58.9M$37.1M-$-14.73M-$-7.05M
Total other income/expenses, net$2.38M-$-1.57M-$-6.48M-$-5.02M-$-5M
Income before tax$66.3M$57.3M$30.6M-$-19.75M-$-12.05M
Income tax expense$17.7M$15.3M-$-36.81M$210K$250K
Net income$48.6M$42.4M$67.4M-$-30.2M-$-12.3M
Weighted average shares outstanding$147.8M$147M$116.5M$112.9M$110.4M
Weighted average diluted shares outstanding$149.7M$149.1M$146M$112.9M$110.4M
Balance sheet
20252024202320222021
Cash and short-term investments$166.1M$104.4M$82M$66M$87.1M
Net receivables$75.7M$55.8M$53.9M$43.1M$40.4M
Inventory$25.3M$23.8M$21M$13.2M$11.4M
Total current assets$277.5M$191.9M$164.3M$134.2M$148.5M
Property, plant and equipment, net$4.71M$11.6M$9.11M$11.3M$13.9M
Goodwill and intangible assets$33.6M$31.1M$24.7M$25.3M$25.4M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$65.2M$72M$74.8M$37.2M$39.4M
Total assets$342.7M$263.9M$239.1M$171.4M$187.9M
Accounts payable$14.5M$7.41M$9.05M$8.45M$7.38M
Short-term debt$2.82M$2.31M$0.00$1.44M$1.25M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$64.3M$45.6M$46M$43.6M$42.4M
Long-term debt$19.7M$22.5M$48.1M$51M$52.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$21.8M$25.2M$50.3M$53.4M$53M
Capital lease obligations$3.25M$6.01M$0.00$2.44M$5.17M
Total liabilities$86.1M$70.8M$96.3M$96.9M$95.4M
Common stock$150K$150K$150K$110K$110K
Retained earnings-$-42.68M-$-91.26M-$-133.68M-$-191.91M-$-161.71M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$256.6M$193.1M$142.7M$74.5M$92.6M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$22.5M$24.8M$48.1M$52.5M$53.3M
Net debt-$-143.59M-$-79.57M-$-33.9M-$-13.48M-$-33.79M
Cash flow statement
20252024202320222021
Net income$48.6M$42M$67.4M-$-19.95M-$-12.3M
Depreciation and amortization$14.9M$6.04M$3.43M$4.05M$5.18M
Stock-based compensation$16.4M$16.9M$17M$11.3M$14.2M
Change in working capital-$-22.98M-$-5.43M-$-18.42M-$-8.01M-$-19.35M
Accounts receivable-$-26.39M-$-2.55M-$-12.24M-$-5.94M-$-10.62M
Inventory-$-1.53M-$-2.36M-$-7.84M-$-1.79M-$-1.41M
Accounts payable$2.12M-$-1.41M$780K$840K-$-160K
Net cash provided by operating activities$74M$66.2M$26.8M-$-17.89M-$-1.98M
Investments in property, plant and equipment-$-1.03M-$-1.68M-$-1.99M-$-1.51M-$-3.22M
Acquisitions, net-$-3.76M-$-7.86M$0.00$0.00$0.00
Net cash used for investing activities-$-6.89M-$-9.58M-$-2.15M-$-2.66M-$-3.4M
Common stock issued$0.00$1.4M$1M$650K$1.44M
Common stock repurchased-$-3.12M-$-2.64M-$-9.52M-$-1.19M-$-4.75M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-5.41M-$-34.2M-$-8.57M-$-580K-$-3.35M
Net change in cash$61.7M$22.4M$16.1M-$-21.13M-$-8.73M
Cash at end of period$166.1M$104.4M$82M$66M$87.1M
Operating cash flow$74M$66.2M$26.8M-$-17.89M-$-1.98M
Capital expenditure-$-1.03M-$-1.68M-$-1.99M-$-1.51M-$-3.22M
Free cash flow$73M$64.5M$24.8M-$-19.41M-$-5.2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MiMedx Group, Inc.

        MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.

        CEO
        Joseph H. Capper
        Employees
        808
        Beta
        1.45

        Explore

        Frequently asked questions

        What is the intrinsic value of MiMedx Group, Inc. (MDXG)?

        MiMedx Group, Inc. (MDXG) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MDXG undervalued?

        MDXG trades at a price of $3.05 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.